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Purpose: The purpose of this project was to determine if mutations, including large insertions or deletions, in the recently
identified RP31 gene topoisomerase I-binding arginine-serine rich (RS) protein (TOPORS), cause an appreciable fraction
of autosomal dominant retinitis pigmentosa (adRP).
Methods: An adRP cohort of 215 families was used to determine the frequency of TOPORS mutations. We looked for
mutations in TOPORS by testing 89 probands from the cohort without mutations in other known adRP genes. Mutation
detection was performed by fluorescent capillary sequencing and by multiplex ligation probe amplification.
Results: Two different TOPORS mutations, p.Glu808X and p.Arg857GlyfsX9, were each identified in one proband.
Patients with these mutations exhibited clinical signs typical of advanced adRP. No large deletions or insertions of
TOPORS were identified in our study.
Conclusions: Point mutations and small insertions or deletions in TOPORS cause approximately 1% of adRP. Large
deletions or insertions of TOPORS are not an appreciable cause of adRP. Contrary to previous reports, no distinct clinical
phenotype was seen in these patients.
Retinitis pigmentosa (RP) is a heterogeneous form of
inherited blindness initially characterized by night blindness
and peripheral vision loss, usually culminating in legal or
complete blindness. Approximately one out of 3,000–4,000
individuals is affected with RP [1]. RP can be inherited in an
autosomal dominant (adRP), autosomal recessive (arRP), or
X-linked (XlRP) pattern and to date, 16 autosomal dominant,
18  autosomal  recessive,  and  six  X-linked  loci  have  been
identified,  with  some  genes  causing  multiple  overlapping
diseases. (RetNet) [2].
Disease-associated genes have been identified for 15 of
the  16  adRP  loci  (RetNet)  [3].  The  most  recent  disease-
associated gene identified was for the RP31 form of adRP
[4]. Mutations in the topoisomerase I-binding arginine-serine
rich (RS) gene (TOPORS) cause RP31 [5]. Initial findings
identified two different TOPORS mutations associated with
disease,  both  of  which  were  small  insertions/deletions
resulting in frame-shifts and premature termination of the
protein. The mutant TOPORS protein was not detected in
lymphoblast cell lines from patients with these mutations.
Examination of additional adRP probands for mutations
in TOPORS will provide information on mutation frequency
and may potentially provide additional biologic information
regarding the disease mechanism. Since haploinsufficiency is
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believed to be the likely disease mechanism associated with
TOPORS mutations, it is possible that large deletions, or copy
number variants (CNV) in TOPORS, may also be a cause of
adRP. This project examines a well defined adRP cohort using
both standard sequencing methodology and multiplex ligation
probe amplification (MLPA) to look for CNVs [6,7].
METHODS
Autosomal  dominant  retinitis  pigmentosa  cohort  and
controls: The cohort of 215 adRP probands used in this study
has been described in detail previously [6-8]. This cohort is a
set of 215 families which, based on pedigree analyses, have a
high  likelihood  of  having  adRP.  Each  proband  has  been
previously tested for mutations in the complete coding region
of
CA4,CRX,FSCN2,IMPDH1,NRL,PRPF31,RDS,RHO,ROM1
,  and  RP9.  Samples  were  also  screened  for  mutations  in
mutational “hot spots” of RP1,PRPF3,PRPF8, and NR2E3.
Likely disease-causing mutations have been identified in 126
of the 215 families. Probands from the remaining 89 families
were tested in this study. A set of 90 unrelated normal control
samples obtained from the Centre dEtude du Polymorphisme
Humain were also tested for the presence of the two mutations
identified in the cohort samples [9].
This  study  was  performed  in  accordance  with  the
Declaration of Helsinki, and informed consent was obtained
from  all  participants.  This  research  was  approved  by  the
Committee  for  the  Protection  of  Human  Subjects  at  the
University of Texas Health Science Center at Houston and by
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922the  respective  human  subjects’  review  boards  at  each
participating institution.
Sequencing  analyses—PCR  product  sequencing  was
employed to screen patient DNA for mutations in the entire
coding  region  and  flanking  intron/exon  junction  of
TOPORS. PCR amplification and sequencing were performed
as previously described using the primers in Table 1 [6].
Briefly, exons 1 and 2 were each amplified using 30–50 ng of
genomic  DNA  and  AmpliTaq  Gold  (Applied  Biosystems,
Foster City, CA) in a 12.5 μl reaction for 35 cycles. Exon 3
was amplified in two pieces using 100 ng of genomic DNA
and either AmpliTaq Gold or HotStarTaq DNA polymerase
(Qiagen, Valencia, CA) with Q-solution, in a 25 μl reaction
for 35–40 cycles.
PCR  products  were  treated  with  ExoSapIt  (USB,
Cleveland, OH) and sequenced unidirectionally with BigDye
v1.1 (Applied Biosystems) and the primers described in Table
1.  Sequence  reactions  were  purified  using  BigDye®
Xterminator Kit (Applied Biosystems) and the manufacturer’s
protocol. Purified reactions were run on an ABI 3100-Avant
Genetic Analyzer (Applied Biosystems) and analyzed using
SeqScape Software (Applied Biosystems).
Multiplex  ligation  probe  amplification  analyses—
MLPA  analyses  were  performed  as  previously  described
using  eight  probe  pairs  designed  to  span  each  of  the
TOPORS amplification primers (Table 2), seven control probe
pairs,  and  the  EK1  kit  (MRC-Holland,  Amsterdam,  The
Netherlands) [7]. Briefly, probes were selected based on the
recommendations of MRC-Holland and Raw-Probe Software
(MRC-Holland). All half probes were synthesized by Sigma
Genosys (The Woodlands, TX) and desalted at the time of
synthesis.
Probe cocktails were hybridized overnight with 25–50 ng
of genomic DNA, ligated, and then PCR amplified according
to the DNA detection-quantification protocol recommended
by  MRC-Holland.  PCR  product  was  diluted  in  deionized
formamide (Applied Biosystems) containing GeneScan-500
LIZ size standards (Applied Biosystems) and run on a 3100-
Avant  Genetic  Analyzer.  Dosage  quotients  (DQs)  were
calculated for each TOPORS probe as described by Stern et
al.  using  GeneMapper  (Applied  Biosystems)  and  Excel
(Microsoft,  Redmond,  WA)  software  [10].  A  DQ  of  1.0
indicated  the  presence  of  two  alleles  while  a  0.5  or  1.5
suggested that either a deletion or duplication of the target
sequence, respectively.
RESULTS
Sequencing analyses: We tested genomic DNA from 89 adRP
probands  for  mutations  in  TOPORS  using  fluorescent
capillary sequencing. This procedure detected likely disease-
causing mutations in two of the probands tested. Each of these
mutations  was  heterozygous,  consistent  with  autosomal
dominant inheritance. A 1 bp deletion at nucleotide 2,569 was
detected  in  the  first  proband  from  family  UTAD102  (c.
2569delA; p.Arg857GlyfsX9). This deletion caused a frame-
shift at amino acid residue 857, and was predicted to result in
the  addition  of  eight  incorrect  amino  acids  followed  by
premature termination. Unfortunately, no additional family
members  were  available  for  testing.  Analysis  of  180
chromosomes from normal controls failed to find this DNA
change.
The second TOPORS mutation was a c.G2422T nonsense
change, which resulted in a p.Glu808X in family RFS169.
Analysis of this mutation in eight additional family members
TABLE 1. PRIMERS USED IN POLYMERASE CHAIN REACTION AMPLIFICATION AND SEQUENCING
Exon Amplification primers (5’-3’)
Annealing
temperature Sequencing primers (5’-3’)
1 ACGTAAGAAGCGGAAGATCG 63 °C Same as amplification
GCCTGGGAGGTTACTGTAAGG
2 GTGGGTCTC GCT CTC TGC 63 °C Same as amplification
CCCATTGTTCCGAATCTCAC
3A TCAAGGTCTTTATTTGCATTTTTG 52 °C TCAAGGTCTTTATTTGCATTTTTG
GCTTCTTCTGGACCAACTGC AGAACAACAACTCCACCG
GCCTTCACAGATTAGTCCC
GAGAAACGATCTACATCATTGTC
AGTTGGCCTCCTTACTGCAA
GACCACTCCTGTACACAGCGAAAAC
TTCTGGGGTCCTCTCAGCTA
GGCTTCTTCTGGACCAACTGC
3B TAGCTGAGAGGACCCCAGAA 58 °C AGTTGGTCCAGAAGAAGCCA
GGAGGAAGAGAGTTTTCACCAA TACAAAACACGGCATTTGGA
AAGACCCGGAGCCTAAGTGT
GATGAAGATTTTTGGTAATGACTG
The above PCR and sequencing primers were used to identify TOPORS mutations in our cohort of adRP patients. For exons 1
and 2, the same primers were used for amplification and sequencing reactions. For exons 3A and 3B, several nested sequencing
primers were used to span each amplified PCR product.
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923demonstrated that this mutation tracks with disease (Figure
1).  This  mutation  was  also  not  found  in  the  180  normal
chromosomes tested. Both of the mutations identified in this
study,  like  those  identified  previously  by  Chakarova  and
colleagues  [5],  resulted  in  premature  termination  of  the
TOPORS protein.
During  our  analyses  we  also  identified  two  missense
changes  not  found  in  database  of  single  nucleotide
polymorphisms  (dbSNP).  The  first  change,  a  p.Pro20Ser
TABLE 2. PROBES USED IN MULTIPLEX LIGATION PROBE AMPLIFICATION
Probe set Probe location* 5′ half probe (5′-3′) Phosphorylated 3′ half probe (5′-3′)
Amp1 Front
32542621–
32542674
GGGTTCCCTAAGGGTTGGA
TGGCGGGTACACCCAGC AGCCCTTAC
pGTAAGAAGCGGAAGATCGTATCCT
CCAGTCTAGATTGGATCTTGCTGG CAC
Amp 1 Back
32542362–
32542421
GGGTTCCCTAAGGGTTGGA
GGCAGCAGTCCGCGGGA GCTGGCGGGAG
pCTGCGGGCCTTACAGTAACCTCCC
AGGCGGTGTCTAGATTGGATCTTG CTGGCAC
Amp 2 Front
32540968–
32541035
GGGTTCCCTAAGGGTTGGA
CTGGGGGGTCTCGCTCTC
TGCCCTGCTTCCGAG
pCTGCCATTGGTGATGAGCCCTTTG
CGTCACATCTAGATTGGATCTTGC TGGCAC
Amp 2 Back
32540731–
32540800
GGGTTCCCTAAGGGTTGGA
CAGCCAGGCCTGCGCCG GCATCCTCCGAG
pGTGAGTGAGATTCGGAACAAT GGG
ACGCGGGGGTCGGAAGGTCTAGAT
TGGATCTTGCTGGCAC
Amp 3A Front
32534380–
32534475
GGGTTCCCTAAGGGTTGGA
CAGTGCCCCTTTATAAA
ATAAAACAAAAGTAATGG
GTCACTTAAGTATTTTCAC
pCAAAATAAGTTTCAAGGTCTTTAT
TTGCATTTTTGTTGAGACTCTAGA
TTGGATCTTGCTGGCAC
Amp 3A Back
32532520–
32532601
GGGTTCCCTAAGGGTTGGA
GAGACAAAAAGAGATCA
AGAACTAGAGATAGCAG TTGGTC
pCAGAAGAAGCCAAACTCTGTCTCT
AAGTAGTGAAAGCACAAGTCTAGA
TTGGATCTTGCTGGCAC
Amp 3B Front
32533017–
32533090
GGGTTCCCTAAGGGTTGGA
GTGTCATTGTTGGGTTTGTT
AAACCACTAGCTGAGAG
pGACCCCAGAACTTGTTGAACTGTC
CTCTGATTCTGAGTCTAGATTGGA TCTTGCTGGCAC
Amp 3B Back
32531257–
32531342
GGGTTCCCTAAGGGTTGGA
GGAAAAAGGAAGAATGT
CGTCTACTGCAGTCTATT TAAAGAT
pGACATTTGGTGAAAACTCTCTTCC
TCCTTACAATATTTTAAATGTCTA
GATTGGATCTTGCTGGCAC
Half probes were designed to anneal to the equivalent genomic sequence as the sequencing amplification primers described in
Table 1. Each probe sequence contains a universal half probe sequence which is underlined. The asterisk indicates the position
on chromosome 9 based on the University of California Santa Cruz human genome assembly of March 2006 (hg18).
Figure  1.  Pedigrees  of  families  with
TOPORS mutations. A: This family has
the  p.Arg857GlyfsX9  (c.2569delA)
mutation. B: RFS169. This family has
the p.Glu808X (c.2422C>T) mutation.
Circles  indicate  females;  squares
indicate males. Black filled symbols are
affected individuals, open symbols are
unaffected  individuals,  and  the  “Q”
indicated  an  individual  in  New  York
who reports being asymptomatic. “E”s
indicate  individuals  who  had  eye
examination  at  either  the  Retina
Foundation of the Southwest or the Jules
Stein  Eye  Institute.  “M”s  indicate
individuals  for  whom  ophthalmic
medical  records  were  reviewed.  Plus
signs  show  individuals  whose  DNA
tested positive for the family's mutation;
minus signs are individuals whose DNA
tested  negative  for  the  family's
mutations.
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924(c.C58T), was found in four apparently unrelated Caucasian
probands. Additional family members from one family were
tested for the presence of the variant. The p.Pro20Ser variant
was not found in four affected individuals or obligate carriers
in this family and hence was not considered disease-causing.
The second variant, p.Thr782Ala (c.A2344G), was found in
two  Caucasian  probands.  Testing  of  additional  family
members showed that this variant also did not track with
disease and therefore, is benign.
Multiplex  ligation  probe  amplification:  Work  recently
published  by  Chakarova  et  al.  [5]  suggested  that
haploinsufficiency  is  the  disease  mechanism  of  TOPORS
mutations.  This  is  based  on  protein  analysis  of  the  two
previously identified TOPORS mutations that, like the ones
found in this study, result in a premature protein termination.
The protein analyses of Chakarova et al. [5] failed to detect
the  mutant  protein  in  lymphoblast  cell  lines  from  either
mutation.
Given  that  haploinsufficiency  is  a  likely  disease
mechanism for TOPORS mutations, it is possible that a gross
deletion  or  CNV  of  TOPORS  would  also  lead  to  retinal
disease. To determine if CNVs are a common cause of RP, we
performed MLPA analyses of TOPORS using a series of eight
custom probe sets designed in our laboratory. These probes
were  designed  to  overlap  with  the  original  amplification
primers used in sequence analysis such that any failure to
amplify would also likely be detected. MLPA analyses of
TOPORS in the 89 individuals from our adRP cohort did not
detect CNVs.
UTAD102—The prospectus was a 52-year-old Hispanic
male with only hand motion vision in both eyes. He had two
brothers and three children diagnosed with RP (Figure 1A).
Extensive bone-spicule-like pigment deposits and severely
attenuated blood vessels were seen bilaterally, consistent with
end stage RP. Optic disc pallor and macular retinal pigment
epithelium atrophy were also present. Goldman visual fields
were not possible due to the patient’s poor vision.
RFS169—The prospectus was a 31-year-old Caucasian
male whose major complaint was difficulty going down steps
and curbs in dim light or at night. He was aware that his
peripheral vision was poor and reported frequent inability to
locate objects. His sister, mother, maternal aunt, maternal
grandfather, maternal great-grandfather, and maternal great
uncle had been diagnosed with RP (Figure 1B). He reported
that his mother had severe night blindness at age 20 and was
now 60 years old with extremely poor vision.
Visual acuity was 20/20–2 OD and 20/20–2 OS. Slit lamp
findings were normal bilaterally. Ophthalmoscopy revealed
clear vitreous ocular uterque (OU) and normal discs. Both
maculas  were  normal  without  edema.  The  midperiphery
contained numerous bone-spicule-like pigment deposits. The
retinal arterioles were slightly narrowed by comparison to the
veins. Static perimetry was obtained with a Humphrey Field
Analyzer (Humphrey Instruments, San Leandro, CA), using
programs 30–2 and 60–2. Sensitivity was minimally disturbed
in the fovea and central 15 °. Sensitivity was zero at most
locations beyond 7.5 ° eccentricity. The 60–2 field showed a
region of preserved function in the lower temporal field.
Visual thresholds following 45 min of dark adaptation
were elevated by 1.5 log unit. Full-field electroretinograms
(ERGs) showed that the International Society for Clinical
Electrophysiology of Vision (ISCEV)-standard rod response
was not detectable. The maximum rod photoresponse to a 4.2
log scot td-sec flash was 10 μV, compared to a lower limit of
normal of 155 μV. Cone b-wave amplitude to 31 Hz flicker
was 6.4 μV, compared to a lower limit of normal of 35 μV.
Cone b-wave implicit time was delayed by 9.3 msec. The
maximum cone photoresponse obtained in the presence of a
3.2 log td background was 7.7 μV, compared to a lower limit
of normal of 33.7 μV.
The sister of the prospectus was 41 years old at the time
of examination. She too was aware of night vision and side
vision impairment. In addition, she complained of poor central
vision.  Ophthalmoscopy  revealed  clear  vitreous  OU  and
normal discs. Both maculae were normal without edema. The
midperiphery contained numerous bone-spicule-like pigment
deposits.  The  retinal  arterioles  were  slightly  narrowed  by
comparison to the veins (Figure 2).
Figure  2.  Fundus  photographs  from
RFS169. Right midpheripheral fundus
(A)  and  right  peripheral  fundus  (B)
photographs from the 41-year-old sister
of  the  proband  from  family  RFS169.
The  midperiphery  of  both  eyes
contained  numerous  bone-spicule-like
pigment  deposits  and  the  retinal
arterioles  were  slightly  narrowed  by
comparison to the veins. There was no
evidence of a perivascular cuff of retinal
pigment epithelium atrophy around the
superior  and  inferior  arcades  in  this
family.
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925Visual  acuity  was  20/20–2  OD  and  20/20–2  OS.
Humphrey perimetric values could only be obtained from the
central four locations on the 30–2 field; all locations were
decreased in sensitivity by at least 20 dB with the exception
of the fovea, where sensitivity was within the normal range.
Full-field  ERGs  showed  that  the  ISCEV-standard  rod
response  was  not  detectable,  as  was  the  maximum  rod
photoresponse. Cone b-wave amplitude to 31 Hz flicker was
0.5 μV, compared to a lower limit of normal of 35 μV. Cone
b-wave implicit time was within the normal range.
Medical record examination also provided some detail
regarding the clinical details of the nuclear family found at the
right of the pedigree (Figure 1B). The oldest affected male
cousin of the prospectus was last examined at age 42. At that
time his visual acuity OU was 20/20. He was reported to have
severe field constriction but no fields were available. Fundus
drawings indicated crescent-like areas of atrophy around the
arcades.  The  younger  brother  of  this  individual  was  last
examined when he was 30 years old. His acuity was 20/30 in
each eye. Humphrey fields measured less than 10 degrees in
each eye, and standard ERGs (no computer averaging) were
not  detectable.  Fundus  appearance  was  typical  for  RP;
specifically there was no note of atrophy around the arcade
vessels.
The youngest affected brother in this nuclear family was
last examined at age 32. His visual acuity was 20/150 in each
eye. He had a long history of keratoconus with corneal grafts
in each eye. Due to these corneal problems, there was no
fundus or visual field information available.
Medical records were not immediately available from the
mother of these three brothers. Results from a self-reported
questionnaire, completed at age 66, indicated that she did not
have any trouble with her vision other than glasses needed for
acuity correction. Specifically, she reported no trouble seeing
at night or with her peripheral vision. This suggests that she
is an asymptomatic carrier of the disease-causing mutation
found in her three affected sons.
DISCUSSION
Based  on  our  analyses,  mutations  in  TOPORS  cause
approximately 1% of adRP. Further, these mutations are most
likely to be nonsense changes or small insertion/deletions that
lead to premature termination of the protein [5]. No CNVs
were  identified  in  this  study,  making  it  unlikely  that
TOPORS CNVs cause an appreciable fraction of adRP. Since
our  adRP  cohort  is  composed  primarily  of  probands  of
Western European origin, it is possible that the TOPORS
mutation  frequency,  like  other  adRP  gene  mutation
frequencies,  could  be  different  in  other  populations  [3].
Additional studies will be needed to address this question.
Chakarova et al. [5] reported finding a unique clinical
phenotype in the large family that originally mapped the RP31
locus. In four children they observed a perivascular cuff of
retinal pigment epithelium atrophy in the superior and inferior
arcades  that  progressed  into  pigmentary  retinopathy  with
choroidal sclerosis. The unique perivascular cuff was not seen
in any of our examined patients, but its absence could easily
be due to the later age at which our patients were examined.
Several  members  of  the  original  RP31  family  were  also
reported to be asymptomatic despite carrying the TOPORS
mutation [4]. One member from the RFS169 family discussed
in this study is known to carry the mutation and has reported
being asymptomatic (Figure 1B).
With  the  addition  of  TOPORS  to  the  list  of  adRP-
asssociated genes, mutations can now be identified in 60% of
individuals  with  adRP  (Figure  3)  [6-8].  Mutations  in  the
remaining 40% of affected individuals remain to be identified.
It is clear that there are still additional adRP genes to be
identified.
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Figure 3. Frequency of autosomal dominant retinitis pigmentosa
mutations  found  in  the  autosomal  dominant  retinitis  pigmentosa
cohort by gene. Gene abbreviations: rhodopsin (RHO); peripherin 2
(PRPH2);  pre-mRNA  processing  factor  31  homolog  (PRPF31);
retinitis  pigmentosa  1  (RP1);  pre-mRNA  processing  factor  8
homolog  (PRPF8);  inosine  monophosphate  dehydrogenase  1
(IMPDH1); retinitis pigmentosa GTPase regulator (RPGR); nuclear
receptor subfamily 2, group E, member 3 (NR2E3); pre-mRNA
processing  factor  3  homolog  (PRPF3);  topoisomerase  I-binding
arginine-serine  rich  gene  (TOPORS);  cone-rod  otx-like
photoreceptor homeobox transcription factor (CRX); retinal outer
segment membrane protein 1 (ROM1). Testing identified mutations
in 60% of our autosomal dominant retinitis pigmentosa cohort of 215
families. Mutations have yet to be identified in the remaining 40%.
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